Type Ii Anti-cd20 Antibody And Anti-cd20/cd3 Bispecific Antibody For Treatment Of Cancer

Abstract

The present invention relates to methods of treating a disease, and methods for reduction of cytokine release associated with the administration of a T-cell activating therapeutic agent. The present invention in particular relates to a Type II anti-CD20 antibody for the use in a method for treating or delaying progression of cancer of an individual, wherein the Type II anti-CD20 antibody is used in combination with an anti-CD20/anti-CD3 bispecific antibody.


Claims

Download Citation


Sign in to the Lens

Feedback